在接受免疫检查点抑制剂治疗的转移性黑色素瘤患者中,NRAS肿瘤突变与皮肤不良事件发生率降低相关。

Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH
{"title":"在接受免疫检查点抑制剂治疗的转移性黑色素瘤患者中,NRAS肿瘤突变与皮肤不良事件发生率降低相关。","authors":"Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH","doi":"10.1016/j.jdin.2024.11.004","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 165-167"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742302/pdf/","citationCount":"0","resultStr":"{\"title\":\"NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors\",\"authors\":\"Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH\",\"doi\":\"10.1016/j.jdin.2024.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":34410,\"journal\":{\"name\":\"JAAD International\",\"volume\":\"18 \",\"pages\":\"Pages 165-167\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742302/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAAD International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666328724001822\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAAD International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666328724001822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JAAD International
JAAD International Medicine-Dermatology
CiteScore
3.60
自引率
0.00%
发文量
169
审稿时长
45 days
期刊最新文献
Heterogeneity among melanoma databases and challenges in sustainability: A survey of the Melanoma Prevention Working Group Prevalence of prurigo nodularis in the United States Real-world experience of the efficacy and safety of guselkumab 100 mg in patients with palmoplantar pustulosis in Korea: A retrospective single-center study Association of vitiligo with immune-checkpoint inhibitor therapy: A systematic review Neighborhood factors and the risk of cutaneous T-cell lymphoma: A systematic review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1